NAICS 541711 · Research And Development In Biotechnology
2 open opportunities · 216 FY2025 awards · $1.08B obligated
Top contractors in this NAICS
- Hoffmann-La Roche INC.$47.5M
- The Emmes Company, LLC$10.7M
- Westat, INC.$3.5M
Hunting recompetes here?
10+ contracts in this NAICS end within 18 months. The largest are listed below — incumbents and end dates included.
All expiring 541711 contracts →Open opportunities
- Development of White Matter Atlases for the Baltimore Longitudinal Study of Aging
- Deadline
- —
- Agency
- —
- Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
- Posted
- Sep 28, 2017
- SHEPHERD 2016
- Deadline
- May 24, 2016
- Agency
- —
- Type
- Presolicitation
- NAICS
- 541711
- Posted
- May 9, 2016
| Title | Agency | Type | NAICS | Posted | Deadline |
|---|---|---|---|---|---|
| Development of White Matter Atlases for the Baltimore Longitudinal Study of Aging | — | Combined Synopsis/Solicitation | 541711 | Sep 28, 2017 | — |
| SHEPHERD 2016 | — | Presolicitation | 541711 | May 9, 2016 | May 24, 2016 |
Largest contracts ending within 18 months
- HHSO100201600030C ↗$80.0M
EO14042 EMERGENT AV7909 ANTHRAX VACCINE
- Ends
- Sep 28, 2026
- Started
- Sep 29, 2016
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541711
- HHSO100201600038C ↗$47.5M
THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002.
- Ends
- Sep 29, 2027
- Started
- Sep 14, 2016
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541711
- HHSN275201700002C ↗$10.7M
DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT
- Ends
- May 27, 2027
- Started
- Jul 27, 2017
- Agency
- National Institutes Of Health
- NAICS
- 541711
- W81XWH15C0048 ↗$3.5M
FREEZE DRIED PLASMA CLINICAL TRIAL FOR BLA RESUBMISSION.
- Ends
- Dec 30, 2026
- Started
- Mar 29, 2015
- Agency
- Defense Health Agency
- NAICS
- 541711
- 70RSAT26FR0000002 ↗$2.6M
NEW FFRDC NBACC 2026 INSURANCE
- Ends
- Mar 17, 2027
- Started
- Mar 18, 2026
- Agency
- Office Of Procurement Operations
- NAICS
- 541711
- 70RSAT25FR0000019 ↗$2.2M
TO AWARD AND FULLY FUND THE NBACC ANALYTIC TASKS FOR FACILITY SUBCONTRACTED SUPPORT AND NECESSARY UPGRADES, MODIFICATIONS, AND REPAIRS FOR 2025 (THE NBACC II EXTENSION).
- Ends
- Sep 28, 2026
- Started
- Sep 29, 2025
- Agency
- Office Of Procurement Operations
- NAICS
- 541711
- 75A50121F33005 ↗$2.2M
SCREENING POTENTIAL MEDICAL COUNTERMEASURES TO CHLORINE GAS IN A SMALL ANIMAL MODEL.
- Ends
- Sep 29, 2026
- Started
- Sep 28, 2021
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 541711
- 70RSAT26FR0000017 ↗$2.0M
NBACC II EXTENSION WORK FOR OTHERS (WFO) TASK ORDER FOR THE EQUIPMENT ACQUISITION AND DEMONSTRATION PROJECT PLANNING FOR GENERATIVE UNCONSTRAINED INTELLIGENT DRUG ENGINEERING (GUIDE), PHASE II.
- Ends
- Jul 1, 2027
- Started
- Jul 2, 2026
- Agency
- Office Of Procurement Operations
- NAICS
- 541711
- 75N93024F00002 ↗$1.7M
PRE-CLINICAL MODELS OF INFECTIOUS DISEASES
- Ends
- Jun 23, 2027
- Started
- Jun 24, 2024
- Agency
- National Institutes Of Health
- NAICS
- 541711
- 75N93019F00131 ↗$1.4M
THIS TASK ORDER IS FOR THE DEVELOPMENT OF A PROTOCOL, CLINICAL TRIAL IMPLEMENTATION, CLOSEOUT AND ANALYSIS OF A PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY OF RMENB+OMV NZ (BEXSERO, GSK) IN PREVENTING N. GONORRHOEAE INFECTION.
- Ends
- Oct 30, 2026
- Started
- Aug 22, 2019
- Agency
- National Institutes Of Health
- NAICS
- 541711
| PIID | Contractor | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|---|
| HHSO100201600030C ↗ | Emergent Product Development Gaithersburg INC. | EO14042 EMERGENT AV7909 ANTHRAX VACCINE | Office Of Assistant Secretary For Preparedness And Response | 541711 | $80.0M | Sep 29, 2016 | Sep 28, 2026 |
| HHSO100201600038C ↗ | Hoffmann-La Roche INC. | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $47.5M | Sep 14, 2016 | Sep 29, 2027 |
| HHSN275201700002C ↗ | The Emmes Company, LLC | DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT | National Institutes Of Health | 541711 | $10.7M | Jul 27, 2017 | May 27, 2027 |
| W81XWH15C0048 ↗ | Westat, INC. | FREEZE DRIED PLASMA CLINICAL TRIAL FOR BLA RESUBMISSION. | Defense Health Agency | 541711 | $3.5M | Mar 29, 2015 | Dec 30, 2026 |
| 70RSAT26FR0000002 ↗ | Battelle National Biodefense Institute, LLC | NEW FFRDC NBACC 2026 INSURANCE | Office Of Procurement Operations | 541711 | $2.6M | Mar 18, 2026 | Mar 17, 2027 |
| 70RSAT25FR0000019 ↗ | Battelle National Biodefense Institute, LLC | TO AWARD AND FULLY FUND THE NBACC ANALYTIC TASKS FOR FACILITY SUBCONTRACTED SUPPORT AND NECESSARY UPGRADES, MODIFICATIONS, AND REPAIRS FOR 2025 (THE NBACC II EXTENSION). | Office Of Procurement Operations | 541711 | $2.2M | Sep 29, 2025 | Sep 28, 2026 |
| 75A50121F33005 ↗ | Battelle Memorial Institute | SCREENING POTENTIAL MEDICAL COUNTERMEASURES TO CHLORINE GAS IN A SMALL ANIMAL MODEL. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $2.2M | Sep 28, 2021 | Sep 29, 2026 |
| 70RSAT26FR0000017 ↗ | Battelle National Biodefense Institute, LLC | NBACC II EXTENSION WORK FOR OTHERS (WFO) TASK ORDER FOR THE EQUIPMENT ACQUISITION AND DEMONSTRATION PROJECT PLANNING FOR GENERATIVE UNCONSTRAINED INTELLIGENT DRUG ENGINEERING (GUIDE), PHASE II. | Office Of Procurement Operations | 541711 | $2.0M | Jul 2, 2026 | Jul 1, 2027 |
| 75N93024F00002 ↗ | University Of Texas Medical Branch At Galveston | PRE-CLINICAL MODELS OF INFECTIOUS DISEASES | National Institutes Of Health | 541711 | $1.7M | Jun 24, 2024 | Jun 23, 2027 |
| 75N93019F00131 ↗ | University Of Alabama At Birmingham | THIS TASK ORDER IS FOR THE DEVELOPMENT OF A PROTOCOL, CLINICAL TRIAL IMPLEMENTATION, CLOSEOUT AND ANALYSIS OF A PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY OF RMENB+OMV NZ (BEXSERO, GSK) IN PREVENTING N. GONORRHOEAE INFECTION. | National Institutes Of Health | 541711 | $1.4M | Aug 22, 2019 | Oct 30, 2026 |